Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DUBLIN, May 5, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CareGuidePro™, a mobile application and web portal that serves as a virtual guide for patients throughout their Medtronic spinal cord stimulation therapy journey. The patient's care team, including physicians and Medtronic, may also use the CareGuidePro platform to help manage and support the patient's experience with spinal cord stimulation.

Medtronic Announces CareGuidePro™, a New Mobile App and Online Platform for Patients to Navigate Their Spinal Cord Stimulation Journey

As TAVI Patient Population Grows, PRO+ TAVI System Launches with Four Valve Sizes and Lowest Delivery Profile DUBLIN, May 3, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Mark of the Evolut™ PRO+ TAVI System – the newest-generation Medtronic TAVI system that builds off the proven self-expanding, supra-annular Evolut TAVI platform. The Evolut PRO+ TAVI System includes four valve sizes with an external pericardial tissue wrap that provides advanced sealing for the largest annular range (for self-expanding TAVI technology) on the market.

Medtronic Announces CE Mark of Evolut™ PRO+ TAVI System for Treatment of Symptomatic Severe Aortic Stenosis Patients in Europe

DUBLIN, April 28, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced results from an interim analysis of the first 171 patients (including 71 roll-ins) treated in the OPTIMIZE PRO clinical study. The post-market, prospective, multi-center study is evaluating procedural outcomes (including pacemaker rate) associated with procedure-related techniques and post-procedure TAVR care pathways when using the self-expanding, supra-annular Evolut™ PRO and PRO+ TAVR systems in patients with symptomatic severe aortic stenosis.

Procedure-Related Techniques and Care Pathways from the OPTIMIZE PRO Clinical Study Show Promising Early Outcomes for Patients Implanted with the Medtronic Evolut™ TAVR System

Minimally Invasive Option Has Potential to Provide Long-Term Management of Lung Malignancies While Protecting Lung Function DUBLIN, April 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the Emprint™ ablation catheter kit – an investigational device not yet approved or cleared in the United States. The catheter is intended to be used in conjunction with the Emprint™ microwave generator and Medtronic lung navigation platform to provide a minimally invasive, localized treatment of malignant lesions in the lung, and it can be used together with standard of care therapy when indicated.

Medtronic Receives FDA Breakthrough Designation for the Emprint™ Ablation Catheter Kit

DUBLIN, April 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced approval from the U.S. Food and Drug Administration (FDA) to proceed with an investigational device exemption (IDE) trial to evaluate its internally developed implantable tibial neuromodulation (TNM) device — a therapy designed to provide relief from symptoms of bladder incontinence. The TITAN 1 Feasibility Study is a prospective, multicenter, feasibility study to characterize the procedure for the implantable TNM device in subjects with bladder incontinence.

Medtronic Receives FDA Approval to Launch Clinical Study for Implantable Tibial Neuromodulation Therapy for Bladder Incontinence

EDEN PRAIRIE, Minn., April 27, 2021 /PRNewswire/ --  NeuroOne Medical Technologies Corporation  (OTCQB: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the appointment of Hijaz Haris, as its Vice President of Marketing.

NeuroOne Appoints Medtronic Veteran, Hijaz Haris, as Vice President of Marketing

DUBLIN and LOS ANGELES, April 26, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, and Surgical Theater today announced a partnership to interface Surgical Theater's SyncAR™ augmented reality (AR) technology with Medtronic's StealthStation™ S8 surgical navigation system. This collaboration will enable neurosurgeons to use AR technology in real-time to enhance visualization during complex cranial procedures.

Medtronic Partners with Surgical Theater to Provide First Augmented Reality Platform for Use in Real-Time During Complex Cranial Procedures

The FDA has approved Medtronic plc's (NYSE: MDT) Pipeline Flex Embolization Device with Shield Technology, a chemically bonded, synthetic coating that helps camouflage the metal implant from blood cells and hides it from the body's typical responses to an invading object. The company celebrated the 10th anniversary of the implant when it was first introduced in the U.S, designed to divert blood flow away from a brain aneurysm and prevent its rupture.

FDA Approves Medtronic's Embolization Device For Stopping Brain Aneurysms

First Patient Receives New Shield Surface Modification, An Advance in Flow Diversion Therapy, at NYU Langone Health DUBLIN, April 21, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for Pipeline™ Flex Embolization Device with Shield Technology™. Medtronic developed Shield Technology, a proprietary breakthrough in biomaterial science, to advance flow diversion therapy by introducing the first surface-modified implant device which demonstrates reduction in material thrombogenicity, a reduction in the tendency of the surface treatment material to create clots.

Medtronic Receives U.S. FDA Approval for Pipeline™ Flex Embolization Device with Shield Technology™

IN.PACT AV Access Trial 24 Month Results Presented as a Podium First at Charing Cross Symposium DUBLIN and LONDON, April 20, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the safety and effectiveness results through 24 months for the IN.PACT AV Access clinical study. The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.1,2 "A patient who receives hemodialysis will often need to have several reinterventions each year to maintain patency and keep critical access sites open and functioning properly," said Andrew Holden, MBChB, FRANZCR, director of interventional radiology at Auckland Hospital and associate professor of radiology at Auckland University.

IN.PACT™ AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

Medtronic plc (MDT) Conversation and Q&A with Medtronic's Cardiac Rhythm Management Business (Transcript)

If you think cyberattacks are scary, what if those attacks were directed at your cardiac pacemaker? Medtronic, a medical device company, has been in hot water over the last couple of years because its pacemakers were getting hacked through their internet-based software updating systems.

Medtronic partners with cybersecurity startup Sternum to protect its pacemakers from hackers

Medtronic's (MDT) recently introduced Medtronic Extended infusion set with longer wearability enhances convenience and comfort, thus improving diabetes care.

Medtronic (MDT) Boosts Diabetes Management via New Infusion Set

The new Micra AV leadless pacemaker proves that good things come in small packages.

Medtronic Is Healing Hearts and Padding Portfolios

DUBLIN, April 14, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today introduced in select European countries the Medtronic Extended infusion set — the first and only infusion set that can be worn for up to 7 days. An infusion set is tubing that delivers insulin from the pump to the body and typically requires a set change every few days.

Medtronic Announces European Launch of World's First Infusion Set with Wear up to Seven Days to Help Reduce Burden for People with Diabetes

Orthofix International

Stratasys

These 3D stocks have proven to be instrumental in improving the quality of healthcare outcomes The post 3 3D Stocks That Can Advance the World of Healthcare appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn't matter if you have $500 in savings or $5 million.

3 3D Stocks That Can Advance the World of Healthcare

Medtronic's (MDT) GI Genius Module is the only commercially available computer-aided detection system which uses artificial intelligence to identify colorectal polyploid.

Medtronic's (MDT) GI Genius Module Gets FDA De Novo Clearance

- The GI Genius™ Module Assists Physicians in Detecting Pre-Cancerous Growths; Potentially Addressing 19 Million Colonoscopies Annually - Transformative AI Colorectal Cancer Prevention  Platform Expands Medtronic Capabilities in Medical Technology Data Analytics and Insights DUBLIN, April 12, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) granted de novo clearance for GI Genius™ intelligent endoscopy module in the United States. The GI Genius module is the first and only commercially available computer-aided detection (CADe) system using artificial intelligence (AI) to identify colorectal polyps.

U.S. FDA Grants De Novo Clearance for First and Only Artificial Intelligence System for Colonoscopy; Medtronic Launches GI Genius™ Intelligent Endoscopy Module

Medtronic's (MDT) ventilator sales are robust and prospects of the Diabetes arm remain strong amid the pandemic.

Medtronic (MDT) Hits New 52-Week High: What's Driving It?

MINNEAPOLIS, April 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its ongoing commitment to health equity for people of color living with diabetes. The company committed investments in partnerships with the American Diabetes Association® (ADA) and T1D Exchange, as well as additional research efforts, to better understand and address these disparities.

Medtronic Announces Ongoing Initiatives to Address Health Equity for People of Color Living with Diabetes

This is a stable investment you can buy and forget about.

Why Medtronic Is a Retiree's Dream Stock

Automatic Data Processing

General Dynamics

Intel

Johnson & Johnson

Eli Lilly

Merck

NIKE

Procter & Gamble

Visa

This monthly series ranks a selection of dividend growth stocks in Dividend Radar, presenting the 10 top-ranked stocks for consideration. To rank stocks, I use DVK Quality Snapshots to get quality scores and sort them in descending order, breaking ties with additional metrics.

10 Dividend Growth Stocks For March 2021

DUBLIN, March 26, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for its Harmony™ Transcatheter Pulmonary Valve (TPV), the first minimally invasive therapy created to treat patients with a specific type of congenital heart defect of the right ventricle (RV), one of the four chambers of the heart, which makes it difficult for blood to travel from the heart to the lungs. The Harmony TPV, which is placed inside a patient's native anatomy during a catheter-based procedure, was designated as a Breakthrough Therapy under FDA's Breakthrough Device Designation (BDD) program, an approval pathway intended to help patients receive more timely access to certain life-saving technologies.

Medtronic Receives FDA Approval for "Breakthrough" Transcatheter Pulmonary Valve Replacement for Patients with Congenital Heart Disease

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?

Medtronic (MDT) Down 2.3% Since Last Earnings Report: Can It Rebound?

Medtronic looks attractive at current levels of $117, as it is up 60% from the levels it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. This marks an underperformance compared to the S&P which has moved 75% since its March 2020 lows, with the resumption.

News for Medtronic Stock (MDT)